Tag: laval-quebec
-
SEC raises concerns about Valeant’s use of ‘Non-GAAP’ measures
The SEC has questioned Valeant's practice of stripping away acquisition-related expenses from its “non-GAAP” or adjusted metrics, given that the drugmaker had been fueling growth through frenzied deal making. In multiple letters, the SEC said Valeant's management is in possession of all the facts and urged for adequate and accurate financial disclosures. “We are concerned…
-
SEC raises concerns about Valeant’s use of ‘Non-GAAP’ measures
The SEC has questioned Valeant's practice of stripping away acquisition-related expenses from its “non-GAAP” or adjusted metrics, given that the drugmaker had been fueling growth through frenzied deal making. In multiple letters, the SEC said Valeant's management is in possession of all the facts and urged for adequate and accurate financial disclosures. “We are concerned…
-
Valeant wants Perrigo’s Papa as its new CEO: CNBC, citing Dow Jones
(Reuters) – Valeant Pharmaceuticals International Inc is seeking to name Perrigo Co Plc's Joseph Papa as its new chief executive, CNBC tweeted, citing Dow Jones.
-
Countries on verge of beating malaria face new threat, study says
By Sebastien Malo NEW YORK (Thomson Reuters Foundation) – Nations on the verge of eliminating malaria risk falling short of their goal, just as it lies within reach, due to funding being shifted elsewhere, researchers said on Thursday. Global aid has moved to areas where malaria remains widespread, while internal domestic funding gets diverted to…
-
AstraZeneca taps gene pioneer Venter for huge drug-hunting sweep
By Ben Hirschler CAMBRIDGE, England (Reuters) – AstraZeneca, working with genome pioneer Craig Venter, is launching a massive gene hunt in the most comprehensive bet yet by a pharmaceutical firm on the potential of genetic variations to unlock routes to new medicines. The initiative, announced on Friday, involves sequencing up to 2 million human genomes…
-
Exclusive: Makers took big price increases on widely used U.S. drugs
By Caroline Humer NEW YORK (Reuters) – Major drug companies took hefty price increases in the U.S., in some cases more than doubling listed charges, for widely used medications over the past five years, a Reuters analysis of proprietary data found. Together, the price increases on drugs for arthritis, high cholesterol, asthma and other common…
-
Valeant seeks waiver from lenders related to filing annual report
The company said earlier in the month that a delay in filing its annual report would put it at risk of a default on its $30 billion in debt. Valeant on Wednesday said it was seeking to extend the deadline for filing its annual report to May 31. “The company is comfortable with its current…
-
The Curse of the Rising Deductible
Nurse Katz, With health care costs and my health insurance deductibles on the rise, how can I assure that I don't go broke just paying my deductible?AmyChevy Chase, MDDear Amy,Unfortunately, this is a common concern for many, which is why I call it the “curse of the rising deductible.” Many people have been forgoing or…
-
Valeant CEO Pearson to return effective immediately, results delayed
By Caroline Humer NEW YORK (Reuters) – Valeant Pharmaceuticals International said on Sunday that Chief Executive Officer Michael Pearson would return from medical leave effective immediately, and it postponed the release of fourth-quarter results planned for Monday. Valeant was under pressure for its drug price increases when it said in late December that Pearson had…
-
Valeant CEO Pearson to return effective immediately, results delayed
By Caroline Humer NEW YORK (Reuters) – Valeant Pharmaceuticals International said on Sunday that Chief Executive Officer Michael Pearson would return from medical leave effective immediately, and it postponed the release of fourth-quarter results planned for Monday. Valeant was under pressure for its drug price increases when it said in late December that Pearson had…